top of page
UroPharma
Home
News
About
Leadership Team
Advisory Board
Business Partners
Consultants
Investor Documents
Testimonials
Technology
The Problem
The Solution
Pipeline Devices
Pipeline Theraputics
Market
Market Opportunity
Primary Research
Secondary Research
Market Entry Strategy
​Research References
Regulatory
ISO Accreditation
Regulatory Timeline
Quality Policy Statement
Contact
Address
Email Us
Privacy Policy
More
Use tab to navigate through the menu items.
Log In
All Posts
Fundraising
Medical Devices
Pharmaceuticals
Bladder Health
Quality of Life
Market Research
Regulatory
Healthcare
Search
Log in / Sign up
Scott Glickman
May 1, 2024
2 min read
OABÂ tablets and patient safety
#Overactivebladder syndrome, (OAB), describing #urinaryurgency of unknown cause, was so named because #urodynamic investigations of...
bottom of page